InhA and KasA are regarded as the main targets of the well-known anti-tuberculosis drug isoniazid (INH) (Slayden and Barry, 2002; Vilcheze and Jacobs, 2014; Unissa et al., 2016). The gene discussed is INHA; the disease is tuberculosis.